Industry News
Biotechnology Industry News
Lexicon CEO Michael Exton told…
Lexicon CEO Michael Exton told Fierce how he set the company's development and financial pathway "on a very different trajectory."
Fosun Pharma has paid $60 million…
Fosun Pharma has paid $60 million for an option on AriBio’s late-phase Alzheimer’s disease program, securing the chance to expand its rights to the asset in exchange for a further $80 million.
Valneva is planning to shrink its…
Valneva is planning to shrink its headcount by up to 15% as the French vaccine developer continues to seek ways to cut costs.
Takeda has ended development of…
Takeda has ended development of its nausea and vomiting drug candidate for strategic reasons, continuing its multi-year struggles in the therapeutic area.
Kyverna Therapeutics has…
Kyverna Therapeutics has officially started a rolling submission to the FDA for miv-cel as the company conducts additional natural history analysis at the agency's request, keeping the candidate on track to be the first autoimmune
If any proof was needed that big…
If any proof was needed that big money is still available for AI drug development, look no further than the 10-figure series B hauled in by Isomorphic Labs.
Boehringer Ingelheim has put up…
Boehringer Ingelheim has put up 407.5 million euros in biobucks to secure global rights to a first‑in‑class antibody Immunitas Therapeutics is developing for chronic inflammatory and autoimmune diseases.
Immunogenicity dragged on the…
Immunogenicity dragged on the efficacy of AstraZeneca’s rare endocrine disorder prospect in a phase 3 trial, causing the $800 million molecule’s response rate to fall short of the bar set by Ascendis Pharma’s Yorvipath.
Bayer has removed a protein…
Bayer has removed a protein therapeutic for hypertension and a treatment for diabetic neuropathic pain from its phase 1 pipeline.
Bristol Myers Squibb has formed a…
Bristol Myers Squibb has formed a broad partnership with Hengrui Pharma, paying $600 million upfront to advance 13 early-stage programs from across the two companies’ pipelines. The deal could be worth up to $15.2 billion.
Adding Inhibrx Biosciences’ OX40…
Adding Inhibrx Biosciences’ OX40 agonist to Keytruda doubled the response rate in a midphase clinical trial, encouraging the biotech to advance a program that reportedly attracted the interest of Merck & Co.
A phase 2 trial of Enterprise…
A phase 2 trial of Enterprise Therapeutics’ cystic fibrosis drug candidate has hit its primary endpoint, furthering the biotech’s pursuit of a target that companies including Vertex have worked on previously.
A quantum tech firm that has…
A quantum tech firm that has collaborated with—and received investment from—Amgen is now planning to go public.
Novo Nordisk has found the latest…
Novo Nordisk has found the latest buyer for one of its orphaned cell therapies.
Leerink Partners analysts slashed…
Leerink Partners analysts slashed their sales forecast for enGene Therapeutics’ bladder cancer candidate after phase 2 data dented their belief that the biotech can match rivals, including Johnson & Johnson.
Odyssey Therapeutics has become…
Odyssey Therapeutics has become the latest biotech to voyage to the public markets via an upsized $304 million IPO this morning.
Not long after the departure of…
Not long after the departure of former CEO Usman Azam, a new leader is taking her Cue in the form of Shao-Lee Lin, M.D., Ph.D. Lin steps into Cue’s president and chief exec spot after
How a fully integrated syringe…
How a fully integrated syringe system helps pharma teams cut risk, time and regulatory burden.
BeOne Medicines has shaken up its…
BeOne Medicines has shaken up its early pipeline, dropping five phase 1 cancer programs and stopping a phase 2 arthritis trial based on new data.
Ascendis Pharma has ended internal…
Ascendis Pharma has ended internal development of its IL-2 candidate, pivoting away from oncology and calling time on an asset it once tipped for accelerated approval.